Inimex receives US$4.5 million in venture financing

Vancouver-based Inimex Pharmaceuticals Inc has received US$4.5 million in syndicated financing for the lead optimization and pre-clinical development of the first drug based on its innate immunity technology platform. The investment was made by a financing syndicate led by BDC Venture Capital and including the Canadian Medical Discoveries Fund and Working Opportunity Fund. Inimex’s platform was developed in collaboration between company and academic scientists and sponsored by Genome Canada. Inimex is seeking an additional US$2-3 million to fund IND studies and an expansion of its product pipeline....